Table 1 Inclusion and Exclusion criteria: A table outlining the inclusion and exclusion criteria used when screening first by title and abstract and then by full text. Papers will be included if they are primary studies of any study design. The population being studied has to be infants born early pre-term up to term. The studies have to be investigating monoclonal antibody prophylaxis compared with no prophylaxis or placebo, on the outcome of recurrent wheeze or asthma. No studies investigating a population of infants with congenital defects will be included, and no other RSV prophylaxis or treatment apart from monoclonal antibody will be considered
Include: | Exclude: |
|---|---|
All study designs | Reviews |
Primary studies, including peer-reviewed and grey literature | Letters |
All ethnicities | Not about prophylaxis |
Population: infants born early pre-term up to term, followed up for 1–10 years | Population: infants with congenital heart defects |
Intervention: RSV prophylaxis with monoclonal antibody | Any other interventions such as RSV prophylaxis or treatment with RSV-specific immune globulins, steroids, vaccines, macrolides etc. |
Comparison: no prophylaxis or placebo | Comparison: different dosing regimen of monoclonal antibody |
Outcome: recurrent wheeze or asthma development | Bronchiolitis caused by other allergens or viruses such as rhinovirus |